Skip to main content
. 2021 Apr 2;13(7):1682. doi: 10.3390/cancers13071682

Figure 7.

Figure 7

Kaplan-Meier survival analysis, stratified for TIGIT- and CD155 positivity. While the survival curves of cases with and without TIGIT+ immune cells followed a similar trend (n = 103) (A), CD155 positivity was associated with a significantly worse survival by log-rank testing (n = 95, p = 0.005, 1.0 vs. 2.4 years) (B).